THALASSEMIA N ME

Subtitle

LASTEST NEWS ON GENE THERAPY

20 November 2019

Vertex, CRISPR's gene-editing treatment for blood disorders shows promise in early data

25 May 2019

REGENXBIO Announces First FDA Approval of a Gene Therapy Based on Its Proprietary NAV® Technology Platform

29 March 2019

Bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia (TDT) Who Do Not Have β0/β0 Genotype

05 October 2018

Bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application for LentiGlobin™ Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia

27 July 2018

Bluebird's first gene therapy gets European fast track

Connection to page is not secure. Link at http://www.pmlive.com/pharma_news/bluebirds_first_gene_therapy_gets_european_fast_track_1246019

10 July 2018

Fetal Gene Editing with Synthetic Nucleotides Cures Beta-Thalassemia in Mice

23 April 2018

Study: Gene Therapy for Blood Disorder Ends Need for Transfusions

19 April 2018

Thalassaemia gene therapy trial shows 'encouraging' results

05 April 2018

Bluebird's gene therapy eliminates blood transfusions for some beta-thalassemia patients

01 March 2017

Gene therapy 'cures' boy of blood disease that affects millions